Impact of glycaemic status on the cardiac effects of empagliflozin when initiated immediately after myocardial infarction : A post-hoc analysis of the EMMY trial
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
Diabetes, obesity & metabolism - 26(2024), 5 vom: 29. Apr., Seite 1971-1975 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sourij, Caren [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 09.04.2024 Date Revised 13.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/dom.15477 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367775387 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367775387 | ||
| 003 | DE-627 | ||
| 005 | 20240415232204.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240130s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/dom.15477 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1375.xml |
| 035 | |a (DE-627)NLM367775387 | ||
| 035 | |a (NLM)38287198 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sourij, Caren |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of glycaemic status on the cardiac effects of empagliflozin when initiated immediately after myocardial infarction |b A post-hoc analysis of the EMMY trial |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.04.2024 | ||
| 500 | |a Date Revised 13.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Letter | |
| 650 | 4 | |a N‐terminal prohormone of brain natriuretic peptide | |
| 650 | 4 | |a empagliflozin | |
| 650 | 4 | |a myocardial infarction | |
| 650 | 4 | |a prediabetes | |
| 650 | 4 | |a sodium‐glucose cotransporter 2 inhibitors | |
| 650 | 4 | |a type 2 diabetes | |
| 650 | 7 | |a Benzhydryl Compounds |2 NLM | |
| 650 | 7 | |a empagliflozin |2 NLM | |
| 650 | 7 | |a HDC1R2M35U |2 NLM | |
| 650 | 7 | |a Glucosides |2 NLM | |
| 700 | 1 | |a Oulhaj, Abderrahim |e verfasserin |4 aut | |
| 700 | 1 | |a Aziz, Faisal |e verfasserin |4 aut | |
| 700 | 1 | |a Tripolt, Norbert J |e verfasserin |4 aut | |
| 700 | 1 | |a Aberer, Felix |e verfasserin |4 aut | |
| 700 | 1 | |a Pferschy, Peter N |e verfasserin |4 aut | |
| 700 | 1 | |a Postula, Marek |e verfasserin |4 aut | |
| 700 | 1 | |a Drexel, H |e verfasserin |4 aut | |
| 700 | 1 | |a Benedikt, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Kolesnik, Ewald |e verfasserin |4 aut | |
| 700 | 1 | |a Pieber, Thomas R |e verfasserin |4 aut | |
| 700 | 1 | |a Bugger, Heiko |e verfasserin |4 aut | |
| 700 | 1 | |a von Lewinski, Dirk |e verfasserin |4 aut | |
| 700 | 1 | |a Sourij, Harald |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diabetes, obesity & metabolism |d 1999 |g 26(2024), 5 vom: 29. Apr., Seite 1971-1975 |w (DE-627)NLM111220432 |x 1463-1326 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2024 |g number:5 |g day:29 |g month:04 |g pages:1971-1975 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/dom.15477 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2024 |e 5 |b 29 |c 04 |h 1971-1975 | ||